我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
339
268 进行中
药物批准
36
批准总数
监管机构
3
监管机构数
成立时间
N/A
进行中（未招募）
266
78.5%
已完成
40
11.8%
尚未招募
2
0.6%
招募中
26
7.7%
终止
5
1.5%
NMPA
National Medical Products Administration
17
EMA
European Medicines Agency
1
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
18
- The eosinophilic esophagitis (EoE) market is projected to grow from $1.8 billion in 2023 to a significantly higher value by 2034, driven by increased disease awareness and healthcare spending. - Three promising therapies—APT-1011 (Ellodi Pharmaceuticals), tezepelumab (AstraZeneca), and ESO-101 (EsoCap)—are advancing through clinical trials with specialized delivery mechanisms targeting the esophagus. - Despite recent approvals of DUPIXENT and JORVEZA, the EoE treatment landscape remains limited, with concerns about safety profiles and standardized dosing guidelines hindering widespread clinical adoption.
